Jan 24–27, 2027 | Beaver Run Conference Center, Breckenridge, CO, United States
              
              Scientific Organizers:
              
                 
                  Ana Carrizosa Anderson, Drew M. Pardoll, Neta Erez, and Ivan Diaz-Padilla
                
                      
            
 
        -
Scientific Organizers: Ana Carrizosa Anderson, Drew M. Pardoll, Neta Erez, and Ivan Diaz-Padilla
Ana Carrizosa Anderson, PhD
Harvard Medical School
Drew M. Pardoll
Johns Hopkins University School of Medicine
Neta Erez, PhD
Weizmann Institute of Science
Ivan Diaz-Padilla, MD, PhD
Ipsen, Oncology Global Research & Development
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Sunday, January 24, 2027
Monday, January 25, 2027
How Tumors Enable Immunotherapy
Lessons from Checkpoint Blockade Trials
Neoadjuvant Checkpoint Blockade in MMRd Cancer
Understanding Resistance to Checkpoint Inhibition based on Neoadjuvant Clinical Trials
Rewiring T Cells in PD1 Resistant Tumors
Stromal and Immune Plasticity Shape the Metastatic Niche
Systems Cancer Pathology
Tuesday, January 26, 2027
Harnessing NK Cells in Cancer Therapies
Targeting Innate T Cells in Cancer (MAIT , gdT, and iNKT)
Macrophage Directed Immunotherapies
Trem2 based Therapies in Cancer
Early CD8+ T Cell Fate Commitment in Cancer
Talk Title to be Announced
Cytokine-Directed Gene Programs Shaping CD8+ T Cell Differentiation in Cancer
Wednesday, January 27, 2027
Engineering T Cell Cancer Therapies
Therapeutic Applications of CRISPR
Bi-Specific T Cell Engagers (BiTes)
Engineering Proteins for Immunotherapy
Novel Mechanisms Producing Targetable Tumor Antigens
Cancer Vaccines for Immunoprevention
Next Generation Cancer Vaccines
Thursday, January 28, 2027
Subscribe for Updates